Search Results for "Gynecology"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Gynecology. Results 1 to 10 of 20 total matches.
Addendum: Ospemifene (Osphena) for Dyspareunia
The Medical Letter on Drugs and Therapeutics • Oct 14, 2013 (Issue 1427)
significant
gynecological abnormality. They also excluded women
who were obese or had hypertension, among ...
Some readers have objected to our recommendation (Med Lett Drugs Ther 2013; 55:55) that postmenopausal women with an intact uterus who take the oral estrogen agonist/antagonist ospemifene (Osphena) to reduce the severity of dyspareunia should also take a progestin.1 Ospemifene has agonistic effects on the endometrium, and the Osphena package insert says: "Generally, when a product with estrogen agonistic effects on the endometrium is prescribed for a postmenopausal woman with a uterus, a progestin should be considered to reduce the risk of endometrial cancer."Endometrial hyperplasia has been...
Robotic-Assisted Laparoscopic Surgery
The Medical Letter on Drugs and Therapeutics • Jun 14, 2010 (Issue 1340)
in recent years
for use in laparoscopic prostatectomy, gynecological
procedures, general surgery ...
The da Vinci Surgical System (Intuitive Surgical, Sunnyvale, CA) has become available in recent years
for use in laparoscopic prostatectomy, gynecological procedures, general surgery, otolaryngology and cardiothoracic procedures.
Misoprostol
The Medical Letter on Drugs and Therapeutics • Mar 10, 1989 (Issue 787)
of women taking misoprostol have reported gynecological disturbances such as spotting and dysmenorrhea ...
Misoprostol (Cytotec - Searle), a synthetic methyl analog of prostaglandin E1, was recently approved by the US Food and Drug Administration for prevention of gastric ulcers in high-risk patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). In other countries, the drug is also marketed for treatment of idiopathic peptic ulcers unrelated to NSAIDs.
Laparoscopic Cholecystectomy
The Medical Letter on Drugs and Therapeutics • Dec 28, 1990 (Issue 834)
currently used for laparoscopic
cholecystectomy, which were designed for gynecological or urological ...
Unlike new drugs, new techniques for surgery do not need the approval of any government agency. Laparoscopic cholecystectomy, made possible by the development of miniaturized television cameras, is one such technique that has recently attracted widespread interest (LW Way, N Engl J Med, 323:1273, Nov 1, 1990; R Winslow, Wall St J, 216:1, Dec 10, 1990).
Ifosfamide and Mesna
The Medical Letter on Drugs and Therapeutics • Nov 03, 1989 (Issue 804)
, 1989; RE Coleman et al, Br J Cancer, 58:273,
1988) and other gynecological malignancies (GP Sutton et ...
Ifosfamide (Ifex - Mead Johnson), a synthetic analog of cyclophosphamide (Cytoxan; and others), has been approved by the US Food and Drug Administration (FDA) for concurrent use with other drugs in third-line chemotherapy of metastatic germ-cell testicular cancer. Given concomitantly, a synthetic sulfhydryl compound known as mesna (Mesnex - Asta) acts in the urine to detoxify metabolites of ifosfamide that cause hemorrhagic cystitis (H Burkert, Cancer Treat Rev, 10 suppl A:175, 1983). Ifosfamide and mesna are available together from Bristol-Myers Oncology Division.
Bromfenac for Analgesia
The Medical Letter on Drugs and Therapeutics • Oct 10, 1997 (Issue 1011)
). A multicenter double-blind trial in 204 patients after abdominal gynecologic surgery found
50-mg bromfenac ...
Bromfenac sodium (Duract - Wyeth-Ayerst), a nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration (FDA) and is being heavily advertised as an alternative to narcotics for short-term treatment of pain.
The Cervical Cap
The Medical Letter on Drugs and Therapeutics • Oct 07, 1988 (Issue 776)
after the first three months of use for a Pap test and every 12 months for gynecological examination ...
The US Food and Drug Administration recently approved the marketing of a cervical cap (Prentif Cavity-Rim Cervical Cap - Lamberts Ltd, England), a contraceptive device that has been used in one form or another for many years (JP Koch, Contraception, 25:161, 1982). The cap is being distributed in the USA and Canada by Cervical Cap (CxC), Ltd, PO Box 38003-292, Los Gatos, CA 95031, telephone 408-358-6264; the distributor will make the caps available only to practitioners who have attended training seminars.
Cefepime (Maxipime) - A New Parenteral Cephalosporin
The Medical Letter on Drugs and Therapeutics • Sep 13, 1996 (Issue 983)
/gynecologic and
intra-abdominal infections, and for empiric treatment of febrile patients with neutropenia ...
Cefepime hydrochloride (Maxipime - Bristol-Myers Squibb), a new 'fourth-generation' cephalosporin, has been approved by the US Food and Drug Administration (FDA) for parenteral treatment of urinary tract infections and skin and skin-structure infections due to susceptible pathogens, and for moderate to severe pneunmonia caused by Streptococcus pneumoniae (pneumococci), Pseudomonas aeruginosa, Enterobacter or Klebsiella pneumoniae.
Trovafloxacin
The Medical Letter on Drugs and Therapeutics • Mar 13, 1998 (Issue 1022)
or pelvic/gynecologic infections. An oral or intravenous dose of
200 mg once daily is recommended ...
Trovafloxacin (Trovan - Pfizer) and its prodrug alatrofoxacin (Trovan IV) are new fluroroquinolones marketed for an unusually wide variety of infections, including oral and intravenous treatment of nosocomial and community-acquired pneumonia, acute ecerbations of chronic bronchitis, acute sinusitis, complicate intra-abdominal and pelvic infections, diabetic foot infection, uncomplicated urinary tract infection, prostatitis, cervicitis and uncomplicated gonorrhea.
COVID-19 Update: FDA Authorizes Novavax COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
pregnancy.4
The American College of Gynecology (ACOG)
recommends vaccination against COVID-19 ...
The FDA has issued an Emergency Use Authorization
(EUA) for an adjuvanted protein subunit COVID-19
vaccine manufactured by Novavax. The vaccine
is indicated for use as a two-dose primary series
to prevent COVID-19 in adults; it is not authorized
for use in children or as a booster dose. Three
other COVID-19 vaccines are available in the US for
primary immunization of adults; the mRNA vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) are FDA-licensed for this indication,
and the adenovirus-based vaccine manufactured
by Johnson & Johnson (Janssen) is...